Final-Program-ATS-2023-AP.vp

314

WEDNESDAY • MAY 24

9:12 Targeting the Signaling Domain of Aminopeptidase N Ameliorates Pulmonary Hypertension/ J. James, Tucson, AZ 9:24 Skeletal Muscle SIRT3 Deficiency Remotely Regulates Pulmonary Vascular Remodeling Via LOXL2-CNPY2-p53 Axis in Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction/ J.-R. Jheng, Indianapolis, IN 9:36 Cybrid Analysis Delineates Nuclear and Mitochondrial Contributions to Oxidative Stress in Pulmonary Arterial Hypertension/ S. Balachandar, Indianapolis, IN 9:48 SOX17 Enhancer Variants Disrupt Transcription Factor

9:12 Nicotine in E-cigarette Aerosols Alters Pulmonary Gene Expression, Increases Lung Protein Permeability, and Impairs Virus Clearance During Influenza Infection in Mice/ M. Maishan, San Francisco, CA 9:24 E-cigarette Whole Body Aerosol Exposure: Acute Cardiovascular Changes and Effects on Subsequent Pneumococcus Infection/ G. Grunig, New York, NY 9:36 Use of Inhaled Corticosteroids and the Risk of Mortality and Hospitalisation for Pneumonia in a UK Cohort of Patients With Idiopathic Pulmonary Fibrosis/ A.D. Morgan, London, United Kingdom 9:48 NF- k B Inhibition Attenuates Human Rhinovirus Replication Following Corticosteroid and Diesel Exhaust Particulate Exposures/ R.D. Huff, Vancouver, Canada

Binding and Enhancer Inactivity Drives Pulmonary Hypertension/ R. Walters, London, United Kingdom

BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

BASIC • TRANSLATIONAL MINI SYMPOSIUM

D19

NEW PERSPECTIVES ON TRANSLATIONAL STUDIES FOR LUNG FIBROSIS

D18

MOLECULAR TRAFFIC HUBS IN PULMONARY VASCULAR DISEASE

8:00 a.m. - 10:00 a.m.

Walter E. Washington Convention Center Room 146 A-C (Street Level)

8:00 a.m. - 10:00 a.m.

Marriott Marquis Downtown Liberty Ballroom, Salons I-L (Level M4)

Chairing: A. Pardo, PhD, Ciudad de Mexico, Mexico

Chairing: A.L. Frump, MS, PhD, Indianapolis, IN S. Umar, MD, PhD, Los Angeles, CA A.J. Bryant, MD, Gainesville, FL

T.M. Maher, MD, MSc, PhD, FRCP, Los Angeles, CA M. Bhattacharya, MD, MSci, San Francisco, CA

Featured Speaker: 8:00 Models to Test Airway Basal Cell Function in IPF/ A. Prasse, Hannover, Germany Oral Presentations: 8:12 Targeting MCT1-mediated Intercellular Lactate Shuttling Attenuates Pulmonary Fibrosis/ C. He, Birmingham, AL 8:24 Targeting RAD51 for the Treatment of Pulmonary Fibrosis/ M. Choudhury, Rochester, MN 8:36 Perivascular Neuronal ß-III Tubulin (Tuj1) Diminishes the Severity of Pulmonary Fibrosis/ R. Sato, Bethesda, MD 8:48 A First-in-Class IL-11 Receptor Blocking Antibody as a Treatment for Pulmonary Fibrosis/ J. Swaney, San Diego, CA 9:00 Dual an ß 6 / an ß 1 Integrin Inhibitor PLN-74809 Attenuates Pathologic Fibroblasts in Human Fibrotic Lung Explant Tissue/ M.C. An, South San Francisco, CA 9:12 Preclinical Pulmonary Fibrosis Models Identify AMP-kinase as a Candidate Druggable Target for Pulmonary Fibrosis Therapies/ K.-D. Alysandratos, Boston, MA 9:24 First-in-class Small-molecule Inhibitor of Nox4 Promotes Reversal of Established Pulmonary Fibrosis/ L. Hecker, Atlanta, GA

J. Aman, MD, PhD, Amsterdam, Netherlands

Oral Presentations: 8:00 Deoxyhypusine Synthase-mediated Hypusination of eIF5A Drives PASMC Proliferation and Vascular Remodeling in Pulmonary Arterial Hypertension/ S.-E. Lemay, Quebec, Canada 8:12 ADAR1 Mediated RNA Editing Contributes to Vascular Remodeling in PAH/ Y. Kim, Boston, MA 8:24 HIPK2/YAP/CEP55 Crosstalk Regulates Pulmonary Vascular Smooth Muscle Cell Proliferation, Survival and Pulmonary Hypertension/ L. Jiang, Davis, CA 8:36 Hypomethylating Drugs Improve Pulmonary Vascular Remodelling and Alleviate Pulmonary Hypertension Development in a Preclinical Model of the Disease/ R. El-Kabbout, Quebec, Canada 8:48 Small Molecule Readthrough Compound GJ103 Effectively Blocks the Development of Heritable Pulmonary Arterial Hypertension in a Mouse Model/ Y. Wang, Torrance, CA 9:00 GALNT1-mediated O-GalNAc Glycosylation Is a Novel Mediator of Pulmonary Arterial Hypertension/ Y. Shi, Indianapolis, IN

ATS 2023 • Washington, DC